FATE1: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: HTTP→HTTPS)
 
imported>Treetear
m (better wikilink but probably not the exact one (which doesnt exist))
 
Line 1: Line 1:
{{Underlinked|date=May 2016}}
 
{{Infobox_gene}}
{{Infobox_gene}}
'''Fetal and adult testis-expressed transcript protein''' is a [[protein]] that in humans is encoded by the ''FATE1'' [[gene]].<ref name="pmid11694338">{{cite journal | vauthors = Olesen C, Larsen NJ, Byskov AG, Harboe TL, Tommerup N | title = Human FATE is a novel X-linked gene expressed in fetal and adult testis | journal = Mol Cell Endocrinol | volume = 184 | issue = 1–2 | pages = 25–32 |date=Nov 2001 | pmid = 11694338 | pmc =  | doi =10.1016/S0303-7207(01)00666-9 }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: FATE1 fetal and adult testis expressed 1| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=89885| accessdate = }}</ref> It is testis-specific in the fetus (aged 6 – 11 weeks). In adults, it is expressed predominantly in the testis, with some expression in the lungs, heart, kidneys, adrenal gland, and throughout the brain.{{citation needed|date=November 2013}}
'''Fetal and Adult Testis-Expressed 1''', encoded by the ''FATE1'' [[gene]] in humans, is a [[protein]] identified as a cancer-testis antigen (CTA) in hepatocellular carcinomas and gastric and colon cancers.<ref name="pmid11694338">{{cite journal | vauthors = Olesen C, Larsen NJ, Byskov AG, Harboe TL, Tommerup N | title = Human FATE is a novel X-linked gene expressed in fetal and adult testis | journal = Molecular and Cellular Endocrinology | volume = 184 | issue = 1-2 | pages = 25–32 | date = November 2001 | pmid = 11694338 | pmc =  | doi = 10.1016/S0303-7207(01)00666-9 }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: FATE1 fetal and adult testis expressed 1| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=89885| access-date = }}</ref><ref name=":0">{{cite journal | vauthors = Doghman-Bouguerra M, Granatiero V, Sbiera S, Sbiera I, Lacas-Gervais S, Brau F, Fassnacht M, Rizzuto R, Lalli E | title = FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria | journal = EMBO Reports | volume = 17 | issue = 9 | pages = 1264–80 | date = September 2016 | pmid = 27402544 | pmc = 5007562 | doi = 10.15252/embr.201541504 | url = http://embor.embopress.org/content/17/9/1264 }}</ref> It is testis-specific in the [[fetus]] (aged 6 – 11 weeks). In adults, it is expressed predominantly in the [[Testicle|testis]] and adrenal glands, with some expression in the lungs, heart, kidneys and throughout the brain.<ref>{{cite journal | vauthors = Dong XY, Su YR, Qian XP, Yang XA, Pang XW, Wu HY, Chen WF | title = Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients | journal = British Journal of Cancer | volume = 89 | issue = 2 | pages = 291–7 | date = July 2003 | pmid = 12865919 | pmc = 2394243 | doi = 10.1038/sj.bjc.6601062 }}</ref><ref>{{cite journal | vauthors = Yang XA, Dong XY, Qiao H, Wang YD, Peng JR, Li Y, Pang XW, Tian C, Chen WF | title = Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues | journal = Laboratory Investigation; A Journal of Technical Methods and Pathology | volume = 85 | issue = 2 | pages = 205–13 | date = February 2005 | pmid = 15580283 | doi = 10.1038/labinvest.3700220 }}</ref>{{citation needed|date=November 2013}}
 
FATE1 is member of the [[mitochondrial fission factor|Miff]] protein family, with its C-terminal domain, consisting of a transmembrane domain with a coiled-coil domain, showing high similarity to the [[MFF (gene)|mitochondrial fission factor (MFF)]] protein which is involved in mitochondrial and peroxisomal fission.<ref name=":0" />
 
== Gene location ==
''FATE1'' gene in humans is located on the long arm of the [[X chromosome]] at region 28, from [[base pair]] 150,884,502 to base pair 150,891,617.<ref name="pmid11694338" /><ref>{{Cite web|url=https://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&q=FATE1|title=AceView: Gene:FATE1, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView.|last=Danielle Thierry-Mieg and Jean Thierry-Mieg,  NCBI/NLM/NIH,|website=www.ncbi.nlm.nih.gov|access-date=2018-11-09}}</ref>
 
== Mechanism ==
It has been hypothesized that FATE1 uses its C-terminal transmembrane domain to attach to [[Endoplasmic reticulum|endoplasmic reticulum (ER)]] membrane and with its C-terminal [[Coiled coil|coiled-coil]] domain it interacts with mitochondria.<ref name=":0" />


==References==
FATE1 is localized in mitochondria-associated ER membranes (MAM) and modulates ER-mitochondria distance to regulate Ca<sup>2+</sup>- and drug dependent apoptosis in cancer cells.<ref name=":0" />
 
FATE1 expression leads to reduction of Ca<sup>2+</sup> uptake by mitochondria and therefore decrease in fragmentation of mitochondria, associated with mitochondrial Ca<sup>2+</sup> uptake, consequently providing protection against cell death.<ref>{{cite journal | vauthors = Szabadkai G, Simoni AM, Bianchi K, De Stefani D, Leo S, Wieckowski MR, Rizzuto R | title = Mitochondrial dynamics and Ca2+ signaling | journal = Biochimica et Biophysica Acta | volume = 1763 | issue = 5-6 | pages = 442–9 | date = 2006-05-01 | pmid = 16750865 | doi = 10.1016/j.bbamcr.2006.04.002 | url = https://www.sciencedirect.com/science/article/pii/S0167488906000802 }}</ref>
 
== Relation to cancer ==
FATE1 is detectable in all cell lines derived from tumors, but is low or undetectable in telomere immortalized, non-tumorigenic fibroblasts and lung epithelial cells. FATE1 is suggested to be essential for survival of tumor cells as depletion of FATE1 results in viability reduction in melanoma, breast, prostate and sarcoma settings.<ref name=":1">{{cite journal | vauthors = Maxfield KE, Taus PJ, Corcoran K, Wooten J, Macion J, Zhou Y, Borromeo M, Kollipara RK, Yan J, Xie Y, Xie XJ, Whitehurst AW | title = Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer | language = En | journal = Nature Communications | volume = 6 | issue = 1 | pages = 8840 | date = November 2015 | pmid = 26567849 | doi = 10.1038/ncomms9840 | url = https://www.nature.com/articles/ncomms9840 }}</ref>
 
Upregulation of FATE1 by a transcription factor [[Steroidogenic factor 1|steroidogenic factor-1 (SF-1)]], involved in adrenal and gonadal development as well as in adrenocortical carcinoma, increases ER-mitochondria distance and is utilized by cancer cell to functionally uncouple ER and mitochondria.<ref name=":0" />
 
Silencing ''FATE1'' gene sensitizes non-small-cell lung cancer cell lines to [[paclitaxel]], a chemotherapeutic drug against many different types of cancers.<ref>{{cite journal | vauthors = Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White MA | title = Synthetic lethal screen identification of chemosensitizer loci in cancer cells | journal = Nature | volume = 446 | issue = 7137 | pages = 815–9 | date = April 2007 | pmid = 17429401 | doi = 10.1038/nature05697 }}</ref>
 
Elevated level of FATE1 is found to be associated with higher mortality rate in colorectal cancers, but in non-small-cell lung cancers, elevation of FATE1 alone did not decrease chance of survival, but decreased if [[RNF183]] expression is also increased.<ref name=":1" />
 
== References ==
{{reflist}}
{{reflist}}


==Further reading==
== Further reading ==
{{refbegin | 2}}
{{refbegin | 2}}
*{{cite journal | vauthors=Hartley JL, Temple GF, Brasch MA |title=DNA cloning using in vitro site-specific recombination |journal=Genome Res. |volume=10 |issue= 11 |pages= 1788–95 |year= 2001 |pmid= 11076863 |doi=10.1101/gr.143000 | pmc=310948  }}
* {{cite journal | vauthors = Hartley JL, Temple GF, Brasch MA | title = DNA cloning using in vitro site-specific recombination | journal = Genome Research | volume = 10 | issue = 11 | pages = 1788–95 | date = November 2000 | pmid = 11076863 | pmc = 310948 | doi = 10.1101/gr.143000 }}
*{{cite journal | vauthors=Olesen C, Hansen C, Bendsen E |title=Identification of human candidate genes for male infertility by digital differential display |journal=Mol. Hum. Reprod. |volume=7 |issue= 1 |pages= 11–20 |year= 2001 |pmid= 11134355 |doi=10.1093/molehr/7.1.11 |display-authors=etal}}
* {{cite journal | vauthors = Olesen C, Hansen C, Bendsen E, Byskov AG, Schwinger E, Lopez-Pajares I, Jensen PK, Kristoffersson U, Schubert R, Van Assche E, Wahlstroem J, Lespinasse J, Tommerup N | title = Identification of human candidate genes for male infertility by digital differential display | journal = Molecular Human Reproduction | volume = 7 | issue = 1 | pages = 11–20 | date = January 2001 | pmid = 11134355 | doi = 10.1093/molehr/7.1.11 }}
*{{cite journal | vauthors=Simpson JC, Wellenreuther R, Poustka A |title=Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing |journal=EMBO Rep. |volume=1 |issue= 3 |pages= 287–92 |year= 2001 |pmid= 11256614 |doi= 10.1093/embo-reports/kvd058 | pmc=1083732 |display-authors=etal}}
* {{cite journal | vauthors = Simpson JC, Wellenreuther R, Poustka A, Pepperkok R, Wiemann S | title = Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing | journal = EMBO Reports | volume = 1 | issue = 3 | pages = 287–92 | date = September 2000 | pmid = 11256614 | pmc = 1083732 | doi = 10.1093/embo-reports/kvd058 }}
*{{cite journal | vauthors=Olesen C, Silber J, Eiberg H |title=Mutational analysis of the human FATE gene in 144 infertile men |journal=Hum. Genet. |volume=113 |issue= 3 |pages= 195–201 |year= 2003 |pmid= 12811541 |doi= 10.1007/s00439-003-0974-9 |display-authors=etal}}
* {{cite journal | vauthors = Olesen C, Silber J, Eiberg H, Ernst E, Petersen K, Lindenberg S, Tommerup N | title = Mutational analysis of the human FATE gene in 144 infertile men | journal = Human Genetics | volume = 113 | issue = 3 | pages = 195–201 | date = August 2003 | pmid = 12811541 | doi = 10.1007/s00439-003-0974-9 }}
*{{cite journal | vauthors=Mehrle A, Rosenfelder H, Schupp I |title=The LIFEdb database in 2006 |journal=Nucleic Acids Res. |volume=34 |issue= Database issue |pages= D415–8 |year= 2006 |pmid= 16381901 |doi= 10.1093/nar/gkj139 | pmc=1347501 |display-authors=etal}}
* {{cite journal | vauthors = Mehrle A, Rosenfelder H, Schupp I, del Val C, Arlt D, Hahne F, Bechtel S, Simpson J, Hofmann O, Hide W, Glatting KH, Huber W, Pepperkok R, Poustka A, Wiemann S | title = The LIFEdb database in 2006 | journal = Nucleic Acids Research | volume = 34 | issue = Database issue | pages = D415-8 | date = January 2006 | pmid = 16381901 | pmc = 1347501 | doi = 10.1093/nar/gkj139 }}
*{{cite journal | vauthors=Lim J, Hao T, Shaw C |title=A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration |journal=Cell |volume=125 |issue= 4 |pages= 801–14 |year= 2006 |pmid= 16713569 |doi= 10.1016/j.cell.2006.03.032 |display-authors=etal}}
* {{cite journal | vauthors = Lim J, Hao T, Shaw C, Patel AJ, Szabó G, Rual JF, Fisk CJ, Li N, Smolyar A, Hill DE, Barabási AL, Vidal M, Zoghbi HY | title = A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration | journal = Cell | volume = 125 | issue = 4 | pages = 801–14 | date = May 2006 | pmid = 16713569 | doi = 10.1016/j.cell.2006.03.032 }}
{{refend}}
{{refend}}


{{gene-X-stub}}
{{gene-X-stub}}

Latest revision as of 23:39, 9 December 2018

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Fetal and Adult Testis-Expressed 1, encoded by the FATE1 gene in humans, is a protein identified as a cancer-testis antigen (CTA) in hepatocellular carcinomas and gastric and colon cancers.[1][2][3] It is testis-specific in the fetus (aged 6 – 11 weeks). In adults, it is expressed predominantly in the testis and adrenal glands, with some expression in the lungs, heart, kidneys and throughout the brain.[4][5][citation needed]

FATE1 is member of the Miff protein family, with its C-terminal domain, consisting of a transmembrane domain with a coiled-coil domain, showing high similarity to the mitochondrial fission factor (MFF) protein which is involved in mitochondrial and peroxisomal fission.[3]

Gene location

FATE1 gene in humans is located on the long arm of the X chromosome at region 28, from base pair 150,884,502 to base pair 150,891,617.[1][6]

Mechanism

It has been hypothesized that FATE1 uses its C-terminal transmembrane domain to attach to endoplasmic reticulum (ER) membrane and with its C-terminal coiled-coil domain it interacts with mitochondria.[3]

FATE1 is localized in mitochondria-associated ER membranes (MAM) and modulates ER-mitochondria distance to regulate Ca2+- and drug dependent apoptosis in cancer cells.[3]

FATE1 expression leads to reduction of Ca2+ uptake by mitochondria and therefore decrease in fragmentation of mitochondria, associated with mitochondrial Ca2+ uptake, consequently providing protection against cell death.[7]

Relation to cancer

FATE1 is detectable in all cell lines derived from tumors, but is low or undetectable in telomere immortalized, non-tumorigenic fibroblasts and lung epithelial cells. FATE1 is suggested to be essential for survival of tumor cells as depletion of FATE1 results in viability reduction in melanoma, breast, prostate and sarcoma settings.[8]

Upregulation of FATE1 by a transcription factor steroidogenic factor-1 (SF-1), involved in adrenal and gonadal development as well as in adrenocortical carcinoma, increases ER-mitochondria distance and is utilized by cancer cell to functionally uncouple ER and mitochondria.[3]

Silencing FATE1 gene sensitizes non-small-cell lung cancer cell lines to paclitaxel, a chemotherapeutic drug against many different types of cancers.[9]

Elevated level of FATE1 is found to be associated with higher mortality rate in colorectal cancers, but in non-small-cell lung cancers, elevation of FATE1 alone did not decrease chance of survival, but decreased if RNF183 expression is also increased.[8]

References

  1. ↑ 1.0 1.1 Olesen C, Larsen NJ, Byskov AG, Harboe TL, Tommerup N (November 2001). "Human FATE is a novel X-linked gene expressed in fetal and adult testis". Molecular and Cellular Endocrinology. 184 (1–2): 25–32. doi:10.1016/S0303-7207(01)00666-9. PMID 11694338.
  2. ↑ "Entrez Gene: FATE1 fetal and adult testis expressed 1".
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Doghman-Bouguerra M, Granatiero V, Sbiera S, Sbiera I, Lacas-Gervais S, Brau F, Fassnacht M, Rizzuto R, Lalli E (September 2016). "FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria". EMBO Reports. 17 (9): 1264–80. doi:10.15252/embr.201541504. PMC 5007562. PMID 27402544.
  4. ↑ Dong XY, Su YR, Qian XP, Yang XA, Pang XW, Wu HY, Chen WF (July 2003). "Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients". British Journal of Cancer. 89 (2): 291–7. doi:10.1038/sj.bjc.6601062. PMC 2394243. PMID 12865919.
  5. ↑ Yang XA, Dong XY, Qiao H, Wang YD, Peng JR, Li Y, Pang XW, Tian C, Chen WF (February 2005). "Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues". Laboratory Investigation; A Journal of Technical Methods and Pathology. 85 (2): 205–13. doi:10.1038/labinvest.3700220. PMID 15580283.
  6. ↑ Danielle Thierry-Mieg and Jean Thierry-Mieg, NCBI/NLM/NIH,. "AceView: Gene:FATE1, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView". www.ncbi.nlm.nih.gov. Retrieved 2018-11-09.
  7. ↑ Szabadkai G, Simoni AM, Bianchi K, De Stefani D, Leo S, Wieckowski MR, Rizzuto R (2006-05-01). "Mitochondrial dynamics and Ca2+ signaling". Biochimica et Biophysica Acta. 1763 (5–6): 442–9. doi:10.1016/j.bbamcr.2006.04.002. PMID 16750865.
  8. ↑ 8.0 8.1 Maxfield KE, Taus PJ, Corcoran K, Wooten J, Macion J, Zhou Y, Borromeo M, Kollipara RK, Yan J, Xie Y, Xie XJ, Whitehurst AW (November 2015). "Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer". Nature Communications. 6 (1): 8840. doi:10.1038/ncomms9840. PMID 26567849.
  9. ↑ Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White MA (April 2007). "Synthetic lethal screen identification of chemosensitizer loci in cancer cells". Nature. 446 (7137): 815–9. doi:10.1038/nature05697. PMID 17429401.

Further reading

Retrieved from "https://www.wikidoc.org/index.php?title=FATE1&oldid=1534231"